Document 2785
 DOCN  M94A2785
 TI    Use of granulocyte colony stimulating factor (G-CSF) in patients with
       HIV infections.
 DT    9412
 AU    Miguelez M; Laynez P; Linarez M; Romero F; Rosquete J; Antolin J;
       Servicio de Medicina Interna Hospital Ntra. Sra. de Candelaria,; Santa
       Cruz de Tenerife, Espana.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):225 (abstract no. PB0329). Unique
       Identifier : AIDSLINE ICA10/94369790
 AB    OBJECTIVE: HIV neutropenia is a common event that may result from
       hematopoietic failure due to infections, secondary to an adverse drug
       toxicity, malignancy and dysmyelopoiesis. G-CSF may have beneficial
       effects in the management of neutropenia in AIDS pts. METHODS: During a
       one-year period, G-CSF were used in 6 HIV infected pts. with severe
       neutropenia. G-CSF was administered at daily doses of 5 mgr/Kgr, s.c.
       RESULTS: Prior to receiving G-CSF the mean base-line absolute neutrophil
       count was < 500/mm3. The mean duration of therapy was 15.2 days (range:
       8-26); the mean absolute neutrophil count at the end of treatment was
       17.560/mm3 (range: 2370-43,000). Cause of neutropenia were felt to be
       secondary to adverse drug toxicity in 3 pts. (2 AZT, 1 chemotherapy for
       HS), opportunistic infections in 1 patient (TB) and dysmyelopoiesis in 2
       pts. All pts were in group IV-C1, according to the classification system
       of the CDC. Temporally bone pain was the only reported toxicity of G-CSF
       in one patient. CONCLUSIONS: G-CSF may have in short term therapy
       beneficial effects in the management of HIV neutropenia.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS/DRUG THERAPY
       AIDS-Related Opportunistic Infections/COMPLICATIONS  Biological Response
       Modifiers/*THERAPEUTIC USE  Comparative Study  Drug Evaluation
       Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE  Human  Leukocyte
       Count  Myelodysplastic Syndromes/COMPLICATIONS
       Neutropenia/ETIOLOGY/*THERAPY  Tuberculosis/COMPLICATIONS
       Zidovudine/ADVERSE EFFECTS/THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).